|Bid price||143.20||Open price||144.90|
|Ask price||143.40||Prev close||143.20|
Register now for FREE live Vectura Group share prices, Vectura Group stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Vectura Group Level 2 Data, indepth research tools and investor commentary for Vectura Group (VEC) and other London Stock Exchange equities.
Register now for FREE Vectura Group share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB00B01D1K48|
|Activites||Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn. Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK). Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy.||Index||FTSE 250|
|Latest Share Price (p)||143.20||Net Gearing (%)||-17.92|
|Market Capitalisation (£m)||981.03||Gross Gearing (%)||17.01|
|Shares in issue (m)||677.98||Debt Ratio||8.28|
|P/E Ratio||120.58||Debt-to-Equity Ratio||0.44|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.21|
|Dividend Yield (%)||0.00||Price to book value||4.14|
|Dividend cover (x)||0.00||ROCE (%)||-0.73|
|Earning per share (p)||1.20||EPS Growth (%)||33.33|
|52 week high / low||179.00 / 122.80||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
|28/09/2016||EXR||Dr Trevor Phillips||ED||510,952|
|28/09/2016||SEXR||Dr Trevor Phillips||ED||240,841|
Vectura Group says it has achieved the £9m calendar year royalty cap on net sales of GSK's Ellipta products in 2016. This was a year earlier than previously guided, and was based on the continued strong performance of Ellipta products and the group's subsequent receipt of its royalty statement...
Story provided by StockMarketWire.com
RNS Number : 0193X Vectura Group plc 16 February 2017 Vectura Group plc Vectura achieves £9 million royalty cap from GSK Ellipta ® products Chippenham, UK, 16 February 2017: Vectura Group plc (LSE: VEC) ("the Group"), an industry-leading inhaled airways...
Register now for FREE Vectura Group company news